JP2016516068A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516068A5
JP2016516068A5 JP2016503207A JP2016503207A JP2016516068A5 JP 2016516068 A5 JP2016516068 A5 JP 2016516068A5 JP 2016503207 A JP2016503207 A JP 2016503207A JP 2016503207 A JP2016503207 A JP 2016503207A JP 2016516068 A5 JP2016516068 A5 JP 2016516068A5
Authority
JP
Japan
Prior art keywords
substituted
group
unsubstituted
aryl
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503207A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516068A (ja
JP6572201B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/029723 external-priority patent/WO2014145068A1/en
Publication of JP2016516068A publication Critical patent/JP2016516068A/ja
Publication of JP2016516068A5 publication Critical patent/JP2016516068A5/ja
Application granted granted Critical
Publication of JP6572201B2 publication Critical patent/JP6572201B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503207A 2013-03-15 2014-03-14 眼疾患を処置するための組成物、製剤、および方法 Active JP6572201B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201361792868P 2013-03-15 2013-03-15
US201361792679P 2013-03-15 2013-03-15
US61/792,679 2013-03-15
US61/792,868 2013-03-15
US201361882056P 2013-09-25 2013-09-25
US201361882048P 2013-09-25 2013-09-25
US61/882,048 2013-09-25
US61/882,056 2013-09-25
US201461934570P 2014-01-31 2014-01-31
US61/934,570 2014-01-31
PCT/US2014/029723 WO2014145068A1 (en) 2013-03-15 2014-03-14 Compositions, formulations and methods for treating ocular diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019147238A Division JP6865254B2 (ja) 2013-03-15 2019-08-09 眼疾患を処置するための組成物、製剤、および方法

Publications (3)

Publication Number Publication Date
JP2016516068A JP2016516068A (ja) 2016-06-02
JP2016516068A5 true JP2016516068A5 (enExample) 2017-04-20
JP6572201B2 JP6572201B2 (ja) 2019-09-04

Family

ID=51529957

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016503207A Active JP6572201B2 (ja) 2013-03-15 2014-03-14 眼疾患を処置するための組成物、製剤、および方法
JP2019147238A Active JP6865254B2 (ja) 2013-03-15 2019-08-09 眼疾患を処置するための組成物、製剤、および方法
JP2021064106A Active JP7249374B2 (ja) 2013-03-15 2021-04-05 眼疾患を処置するための組成物、製剤、および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019147238A Active JP6865254B2 (ja) 2013-03-15 2019-08-09 眼疾患を処置するための組成物、製剤、および方法
JP2021064106A Active JP7249374B2 (ja) 2013-03-15 2021-04-05 眼疾患を処置するための組成物、製剤、および方法

Country Status (17)

Country Link
US (10) US9440963B2 (enExample)
EP (3) EP4101297A1 (enExample)
JP (3) JP6572201B2 (enExample)
KR (1) KR20150129019A (enExample)
CN (2) CN105307498B (enExample)
AU (2) AU2014233363B2 (enExample)
BR (1) BR112015023753A2 (enExample)
CA (1) CA2903871A1 (enExample)
ES (2) ES2928162T3 (enExample)
GB (3) GB2516561B (enExample)
HK (2) HK1206558A1 (enExample)
IL (2) IL240786B (enExample)
MX (1) MX371382B (enExample)
MY (1) MY171945A (enExample)
PH (2) PH12015502153B1 (enExample)
SG (1) SG11201507131WA (enExample)
WO (1) WO2014145068A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
BRPI1006897A2 (pt) 2009-07-06 2015-09-08 Akebia Therapeutics Inc compostos, composições e métodos de prevenção da metástase de células cancerosas.
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
WO2011053251A1 (en) 2009-10-30 2011-05-05 Ix Biopharma Pte Ltd Fast dissolving solid dosage form
CA2774039A1 (en) 2009-11-06 2011-05-12 Aerpio Therapeutics Inc. Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
US20180092883A1 (en) * 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
CN103347561B (zh) 2010-12-08 2016-09-07 康沃特克科技公司 用于评估伤口分泌液的集成系统
EP2648794B1 (en) 2010-12-08 2019-08-28 ConvaTec Technologies Inc. Wound exudate system accessory
EP3501536B1 (en) 2011-10-13 2025-12-24 EyePoint Pharmaceuticals, Inc. Treatment of ocular disease
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
CN107669649A (zh) * 2012-10-11 2018-02-09 Ix生物制药有限公司 固体剂型
JP6572201B2 (ja) * 2013-03-15 2019-09-04 エアーピオ セラピューティクス インコーポレイテッド 眼疾患を処置するための組成物、製剤、および方法
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
ES2739625T3 (es) 2014-02-19 2020-02-03 Aerpio Therapeutics Inc Proceso para la preparación de N-bencil-3-hidroxi-4-sustituido-piridin-2-(1H)-onas
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
EP3364674B1 (en) * 2015-11-06 2019-10-09 Huawei Technologies Co., Ltd. Voice roaming method, mobility management network element, and access network element
SG10201912556VA (en) 2016-07-20 2020-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
CN109996440A (zh) * 2016-10-21 2019-07-09 曼宁研究有限公司 Ve-ptp敲除
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF
EP3956021A4 (en) * 2019-04-18 2023-06-14 EyePoint Pharmaceuticals, Inc. METHOD OF TREATMENT OF HIGH BLOOD PRESSURE WITH ACTIVATORS OF TIE-2
JP7564824B2 (ja) * 2019-04-29 2024-10-09 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
US11413242B2 (en) 2019-06-24 2022-08-16 EyePoint Pharmaceuticals, Inc. Formulations of Tie-2 activators and methods of use thereof
US11613534B2 (en) 2019-10-29 2023-03-28 EyePoint Pharmaceuticals, Inc. Small molecule activators of Tie-2
JP2023530457A (ja) * 2020-06-16 2023-07-18 リプカ，エイミー 小分子ｖｅ－ｐｔｐ阻害剤
CN116940355A (zh) * 2020-12-18 2023-10-24 视点制药公司 用于制造tie-2的小分子激活剂的方法
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2025128706A1 (en) * 2023-12-11 2025-06-19 Massachusetts Eye And Ear Infirmary Methods of using tie-2 activators

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078486A (en) 1989-10-13 1992-01-07 Evans David W Self-calibrating vision test apparatus
US5688781A (en) * 1994-08-19 1997-11-18 Bristol-Myers Squibb Company Method for treating vascular leak syndrome
CA2216963C (en) 1995-04-06 2010-06-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligands, methods of making and uses thereof
US20030040463A1 (en) 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
US6455031B1 (en) * 1997-06-18 2002-09-24 David G Davies Methods and compositions for controlling biofilm development
US5919813C1 (en) 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
US5980929A (en) 1998-03-13 1999-11-09 Johns Hopkins University, School Of Medicine Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
US6455035B1 (en) * 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
NZ514434A (en) 1999-03-26 2003-11-28 Univ California Modulation of vascular permeability by means of TIE2 receptor activators
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
PT1292335E (pt) 2000-06-23 2007-08-13 Bayer Schering Pharma Ag Combinações e composições que interferem na função de receptores vegf/vegf e angiopoietina/ tie e a sua utilização (ii)
PL362979A1 (en) * 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
SE518981C2 (sv) 2000-12-14 2002-12-17 Shl Medical Ab Autoinjektor
US7166435B2 (en) * 2001-08-06 2007-01-23 The Quigley Corporation Compositions and methods for reducing the transmissivity of illnesses
US20030158199A1 (en) * 2002-01-25 2003-08-21 Kylix, B.V. Novel compounds for inhibition of Tie-2
AU2003231098A1 (en) 2002-04-25 2003-11-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
JP2006504743A (ja) * 2002-10-09 2006-02-09 コーザン バイオサイエンシス インコーポレイテッド 治療製剤
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
US6946479B2 (en) 2002-11-09 2005-09-20 The Procter & Gamble Company N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
WO2004060373A1 (ja) * 2002-12-27 2004-07-22 Santen Pharmaceutical Co., Ltd. 滲出型加齢黄斑変性治療剤
AU2004229392A1 (en) * 2003-04-09 2004-10-28 Exelixis, Inc. Tie-2 modulators and methods of use
RS20150135A1 (sr) * 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
WO2005118639A1 (en) * 2004-06-02 2005-12-15 Valtion Teknillinen Tutkimuskeskus Method for activating of t cell protein tyrosine phosphatase and therapeutical methods based thereon
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
EP1968594B1 (en) 2005-11-29 2010-09-29 GlaxoSmithKline LLC Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
EP1962903B1 (en) 2005-12-15 2013-03-13 MedImmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
EP1982718A4 (en) * 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF CANCER
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) * 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
WO2008027013A2 (en) * 2006-08-29 2008-03-06 National Cancer Centre Combination of mtor antagonist and angiogenesis inhibitor for the treatment of cancer
US8957022B2 (en) 2006-10-27 2015-02-17 Sunnybrook Health Sciences Centre Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
ATE514443T1 (de) 2006-12-13 2011-07-15 Shl Group Ab Autoinjektor
US8235952B2 (en) 2007-03-23 2012-08-07 Shl Group Ab Auto injector
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
JP4992147B2 (ja) 2007-07-06 2012-08-08 エス・ホー・エル・グループ・アクチボラゲット 二重ばねを有するワンショット注射器
WO2009037141A1 (en) 2007-09-18 2009-03-26 Shl Group Ab Automatic injection device with needle insertion
WO2009123211A1 (ja) * 2008-03-31 2009-10-08 株式会社資生堂 血管の成熟化、正常化又は安定化剤及びしわ防止・改善剤
WO2009141219A1 (en) 2008-05-20 2009-11-26 Shl Group Ab Device for a medicament delivery device
EP2296732B1 (en) 2008-06-11 2014-02-26 SHL Group AB Medicament delivery device
CN102813689B (zh) * 2008-06-18 2016-08-10 株式会社资生堂 淋巴管的稳定剂
JP4751482B2 (ja) * 2008-07-22 2011-08-17 株式会社メニコン コンタクトレンズ用液剤
WO2010073627A1 (ja) 2008-12-22 2010-07-01 株式会社フジクラ フィルムアンテナ及びその製造方法
PT2385763T (pt) 2009-01-12 2018-07-13 Aerpio Therapeutics Inc Métodos para tratar o síndrome de extravasamento vascular
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
BRPI1006897A2 (pt) 2009-07-06 2015-09-08 Akebia Therapeutics Inc compostos, composições e métodos de prevenção da metástase de células cancerosas.
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
TWI393578B (zh) 2009-07-07 2013-04-21 瑞健集團股份有限公司 注射裝置
TW201105363A (en) * 2009-07-14 2011-02-16 Univ Yamagata Eye drop for macular edema treatment
CA2774039A1 (en) 2009-11-06 2011-05-12 Aerpio Therapeutics Inc. Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
JP2011201811A (ja) * 2010-03-25 2011-10-13 Shiseido Co Ltd Ｔｉｅ２活性化剤、血管の成熟化、正常化又は安定化剤、リンパ管安定化剤並びにしわ防止・改善剤及びむくみ改善・予防剤
US20110319455A1 (en) 2010-04-19 2011-12-29 Bruce Steven Klein Antifungal Treatment
WO2011134056A1 (en) * 2010-04-28 2011-11-03 Sunnybrook Health Sciences Centre Methods and uses of tie2 binding and/or activating agents
US20180092883A1 (en) 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
CA2818215C (en) * 2010-10-07 2015-07-21 Aerpio Therapeutics Inc. Compositions and methods for treating ocular edema, neovascularization and related diseases
EP2857032A3 (en) * 2010-12-02 2015-07-15 Maruzen Pharmaceuticals Co., Ltd. Tie2 activator, vascular endothelial growth factor (vegf) inhibitor, anti-angiogenic agent, agent for maturing blood vessels, agent for normalizing blood vessels, agent for stabilizing blood vessels, and pharmaceutical composition
CN102532042A (zh) * 2010-12-30 2012-07-04 上海医药工业研究院 一种芳基脲类化合物、其中间体及其应用
AU2012214146A1 (en) 2011-02-11 2013-08-29 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
EP3501536B1 (en) 2011-10-13 2025-12-24 EyePoint Pharmaceuticals, Inc. Treatment of ocular disease
JP6572201B2 (ja) 2013-03-15 2019-09-04 エアーピオ セラピューティクス インコーポレイテッド 眼疾患を処置するための組成物、製剤、および方法
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US20160151410A1 (en) 2013-07-02 2016-06-02 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
ES2739625T3 (es) 2014-02-19 2020-02-03 Aerpio Therapeutics Inc Proceso para la preparación de N-bencil-3-hidroxi-4-sustituido-piridin-2-(1H)-onas
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9719135B2 (en) * 2014-07-03 2017-08-01 Mannin Research Inc. Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system

Similar Documents

Publication Publication Date Title
JP2018528273A5 (enExample)
Fernandez et al. N-Succinyl-(β-alanyl-l-leucyl-l-alanyl-l-leucyl) doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity
CN105307498B (zh) 用于治疗眼病的组合物、制剂和方法
JP6968921B2 (ja) 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション
JP2018518537A5 (enExample)
TW201332574A (zh) 煙曲黴素衍生物－ｐｈｆ共軛物之醫藥調配物
AU2014273983A1 (en) Cyclodextrin-based polymers for the therapeutic delivery
JP2010524963A5 (enExample)
WO2004089418A1 (en) A fluoroquinolone aqueous formulation of a ph between 4 and 7 comprising i.a. cyclodextrin, hydroxyacid
CN111344018B (zh) 聚乙二醇化卡非佐米化合物的稳定的组合物
JP2019511497A5 (enExample)
JP2010535198A (ja) コハク酸のコリン塩を含む鼻腔内投与用医薬品組成物
JP2024112842A (ja) Ｍｃｌ１タンパク質を阻害する化合物を投与するための製剤及び投与量
JP2017506640A5 (enExample)
RU2018101473A (ru) Депо-препарат, содержащий сложный эфир лимонной кислоты
CN110876259A (zh) 注射用组合物
JP2020526497A (ja) 合成バイオコンジュゲート
US20190175702A1 (en) Formulations of fosaprepitant and aprepitant
JP2013532664A5 (enExample)
US20180015170A1 (en) Cyclodextrin-based polymers for therapeutic delivery
ES2749053T3 (es) Polimixinas de baja sustitución y sus composiciones
US20210228577A1 (en) Substituted cyclodextrin-metal complexes and uses thereof
RU2018142381A (ru) Фармацевтический препарат
JP6931257B2 (ja) レバミピドを含有する新規ドライアイ治療用点眼組成物及びその可溶化及び安定化方法
FI3519050T3 (fi) Koostumuksia silmätautien hoitamiseksi